Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute Hemodynamic Effects of Riociguat in Pulmonary Hypertension Associated with Diastolic Heart Failure (DILATE 1)
2010-018436-41Phase 2Terminated
- Sponsor
- Bayer
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of riociguat in pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) and Plexogenic Pulmonary Arteriopathy (4 cohorts), sponsored by Bayer. Primary endpoint: Peak decrease from baseline in mean pulmonary arterial pressure. Started Apr 2010; status: terminated.
02
Drugs
riociguat
03
Conditions
pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF)Plexogenic Pulmonary Arteriopathy
Beyond the preview
Go deeper on 2010-018436-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018436-41.